Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations

Leukemia. 2024 Jun;38(6):1415-1418. doi: 10.1038/s41375-024-02248-0. Epub 2024 Apr 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Blast Crisis* / drug therapy
  • Blast Crisis* / genetics
  • Blast Crisis* / pathology
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Imidazoles* / administration & dosage
  • Imidazoles* / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / pathology
  • Mice
  • Mutation*
  • Niacinamide / analogs & derivatives
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles
  • Pyridazines* / administration & dosage
  • Pyridazines* / therapeutic use

Substances

  • Pyridazines
  • ponatinib
  • Imidazoles
  • asciminib
  • Fusion Proteins, bcr-abl
  • Protein Kinase Inhibitors
  • Niacinamide
  • Pyrazoles